Ferring Pharmaceuticals Ltd is a global biopharmaceutical company specializing in areas such as reproductive medicine, maternal health, gastroenterology, and urology. Established over 70 years ago, Ferring has developed a strong reputation for research-driven innovation and patient-centric therapies. It registered in the EU Transparency Register on 14 December 2021 to engage in lobbying activities within the EU institutions. Ferring’s lobbying focus spans policy areas including pharmaceuticals regulation, healthcare innovation, and patient access to medicines. The firm aims to support sustainable healthcare development across Europe and advocates for regulatory frameworks that facilitate clinical research and the introduction of novel therapies, such as gene-based treatments for bladder cancer.
The company operates through a decentralized commercial structure divided into geographical areas including the U.S., Western Europe and Canada, Intercontinental, Japan and nearby Asia-Pacific countries, and Greater China. This network supports its lobbying efforts by aligning local and regional policy strategies with broader EU regulatory goals.
Ferring’s lobbying activities are underpinned by significant investment in innovation and sustainability, reflected in its 2024 annual report revenue of €2.343 billion and continued financial growth. The firm is active in collaborative projects, regulatory consultations, and stakeholder dialogues to foster public health advancements. Additionally, Ferring maintains registrations not only with the EU Transparency Register but also with registers in France and Germany, underscoring its commitment to transparency and compliance in multiple jurisdictions.
By engaging with policymakers, healthcare stakeholders, and industry peers, Ferring Pharmaceuticals Ltd advocates for policies that balance patient needs, scientific advancements, and healthcare system sustainability. Their efforts focus on shaping legislation and policies that impact pharmaceutical innovation, clinical trials, market access, and ethical business conduct within the EU.
